vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Koppers Holdings Inc. (KOP). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($749.2M vs $432.7M, roughly 1.7× Koppers Holdings Inc.). Koppers Holdings Inc. runs the higher net margin — 6.9% vs 3.6%, a 3.2% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs -9.3%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs -6.7%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Koppers is a global chemical and materials company based in Pittsburgh, Pennsylvania, United States. Its headquarters is an art-deco 1920s skyscraper, the Koppers Tower.

CLOV vs KOP — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.7× larger
CLOV
$749.2M
$432.7M
KOP
Growing faster (revenue YoY)
CLOV
CLOV
+71.3% gap
CLOV
62.0%
-9.3%
KOP
Higher net margin
KOP
KOP
3.2% more per $
KOP
6.9%
3.6%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
45.0%
-6.7%
KOP

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLOV
CLOV
KOP
KOP
Revenue
$749.2M
$432.7M
Net Profit
$27.3M
$29.7M
Gross Margin
25.6%
Operating Margin
3.6%
11.5%
Net Margin
3.6%
6.9%
Revenue YoY
62.0%
-9.3%
Net Profit YoY
391.2%
EPS (diluted)
$0.05
$1.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
KOP
KOP
Q1 26
$749.2M
Q4 25
$487.7M
$432.7M
Q3 25
$496.6M
$485.3M
Q2 25
$477.6M
$504.8M
Q1 25
$462.3M
$456.5M
Q4 24
$337.0M
$477.0M
Q3 24
$331.0M
$554.3M
Q2 24
$356.3M
$563.2M
Net Profit
CLOV
CLOV
KOP
KOP
Q1 26
$27.3M
Q4 25
$-49.3M
$29.7M
Q3 25
$-24.4M
$23.8M
Q2 25
$-10.6M
$16.4M
Q1 25
$-1.3M
$-13.9M
Q4 24
$-22.1M
$-10.2M
Q3 24
$-9.2M
$22.8M
Q2 24
$7.4M
$26.8M
Gross Margin
CLOV
CLOV
KOP
KOP
Q1 26
Q4 25
25.6%
Q3 25
24.1%
Q2 25
22.6%
Q1 25
23.2%
Q4 24
17.5%
Q3 24
24.5%
21.9%
Q2 24
30.3%
21.6%
Operating Margin
CLOV
CLOV
KOP
KOP
Q1 26
3.6%
Q4 25
-10.1%
11.5%
Q3 25
-4.9%
10.7%
Q2 25
-2.2%
7.7%
Q1 25
-0.3%
5.9%
Q4 24
-6.4%
1.3%
Q3 24
-2.7%
9.0%
Q2 24
2.0%
10.2%
Net Margin
CLOV
CLOV
KOP
KOP
Q1 26
3.6%
Q4 25
-10.1%
6.9%
Q3 25
-4.9%
4.9%
Q2 25
-2.2%
3.2%
Q1 25
-0.3%
-3.0%
Q4 24
-6.6%
-2.1%
Q3 24
-2.8%
4.1%
Q2 24
2.1%
4.8%
EPS (diluted)
CLOV
CLOV
KOP
KOP
Q1 26
$0.05
Q4 25
$1.44
Q3 25
$1.17
Q2 25
$0.81
Q1 25
$-0.68
Q4 24
$-0.47
Q3 24
$1.09
Q2 24
$1.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
KOP
KOP
Cash + ST InvestmentsLiquidity on hand
$177.6M
Total DebtLower is stronger
$928.3M
Stockholders' EquityBook value
$339.4M
$574.0M
Total Assets
$697.7M
$1.9B
Debt / EquityLower = less leverage
1.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
KOP
KOP
Q1 26
$177.6M
Q4 25
$78.3M
Q3 25
Q2 25
Q1 25
Q4 24
$194.5M
Q3 24
$288.0M
Q2 24
$254.8M
Total Debt
CLOV
CLOV
KOP
KOP
Q1 26
Q4 25
$928.3M
Q3 25
$932.9M
Q2 25
$977.5M
Q1 25
$989.0M
Q4 24
$939.5M
Q3 24
$989.4M
Q2 24
$1.0B
Stockholders' Equity
CLOV
CLOV
KOP
KOP
Q1 26
$339.4M
Q4 25
$308.7M
$574.0M
Q3 25
$340.9M
$545.6M
Q2 25
$344.2M
$526.8M
Q1 25
$336.1M
$498.0M
Q4 24
$341.1M
$488.7M
Q3 24
$342.2M
$532.3M
Q2 24
$324.9M
$509.2M
Total Assets
CLOV
CLOV
KOP
KOP
Q1 26
$697.7M
Q4 25
$541.0M
$1.9B
Q3 25
$559.7M
$1.9B
Q2 25
$575.0M
$1.9B
Q1 25
$583.7M
$1.9B
Q4 24
$580.7M
$1.9B
Q3 24
$653.0M
$2.0B
Q2 24
$674.2M
$1.9B
Debt / Equity
CLOV
CLOV
KOP
KOP
Q1 26
Q4 25
1.62×
Q3 25
1.71×
Q2 25
1.86×
Q1 25
1.99×
Q4 24
1.92×
Q3 24
1.86×
Q2 24
1.97×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
KOP
KOP
Operating Cash FlowLast quarter
$45.1M
Free Cash FlowOCF − Capex
$28.5M
FCF MarginFCF / Revenue
6.6%
Capex IntensityCapex / Revenue
3.8%
Cash ConversionOCF / Net Profit
1.52×
TTM Free Cash FlowTrailing 4 quarters
$67.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
KOP
KOP
Q1 26
Q4 25
$-66.9M
$45.1M
Q3 25
$12.1M
$49.6M
Q2 25
$5.4M
$50.5M
Q1 25
$-16.3M
$-22.7M
Q4 24
$34.8M
$74.7M
Q3 24
$50.0M
$29.8M
Q2 24
$44.8M
$27.2M
Free Cash Flow
CLOV
CLOV
KOP
KOP
Q1 26
Q4 25
$-69.0M
$28.5M
Q3 25
$11.4M
$37.6M
Q2 25
$4.8M
$38.4M
Q1 25
$-16.5M
$-37.0M
Q4 24
$33.3M
$56.1M
Q3 24
$49.6M
$14.4M
Q2 24
$44.4M
$10.1M
FCF Margin
CLOV
CLOV
KOP
KOP
Q1 26
Q4 25
-14.1%
6.6%
Q3 25
2.3%
7.7%
Q2 25
1.0%
7.6%
Q1 25
-3.6%
-8.1%
Q4 24
9.9%
11.8%
Q3 24
15.0%
2.6%
Q2 24
12.5%
1.8%
Capex Intensity
CLOV
CLOV
KOP
KOP
Q1 26
Q4 25
0.4%
3.8%
Q3 25
0.1%
2.5%
Q2 25
0.1%
2.4%
Q1 25
0.0%
3.1%
Q4 24
0.5%
3.9%
Q3 24
0.1%
2.8%
Q2 24
0.1%
3.0%
Cash Conversion
CLOV
CLOV
KOP
KOP
Q1 26
Q4 25
1.52×
Q3 25
2.08×
Q2 25
3.08×
Q1 25
Q4 24
Q3 24
1.31×
Q2 24
6.04×
1.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

KOP
KOP

Other$127.8M30%
Railroad Treated Products$119.0M28%
Utility Poles$79.8M18%
Pitch And Related Products$74.1M17%
Carbon Black Feedstock And Distillates$14.4M3%
Railroad Infrastructure Products And Services$9.9M2%
Phthalic Anhydride Naphthalene And Other Chemicals$7.7M2%

Related Comparisons